Grey literature refers to materials outside peer-reviewed journal articles which may add context or contain lesser-known findings. Paez noted that grey literature may include “academic papers, theses and dissertations, research and committee reports, government reports, conference papers, and ongoing research” .
Campbell J. How (and why) to stop using DHT inhibitors finasteride & dutasteride. July 29, 2021. Accessed July 16, 2022.
Clearfield W. Post Finasteride Syndrome. Post includes slides for presentation to American Osteopathic Society of Rheumatic Diseases – Congress of Medical Excellence 3.0 (dated March 21, 2021); and white paper (undated). May 4, 2021. Accessed July 16, 2022.
Hoffman R. Advocacy group spin may skew discussion on finasteride side effects. HealthNewsReview.org. August 12, 2015. Accessed July 16, 2022.
Jacobs A. A potentially new treatment for post-finasteride syndrome. March 2, 2022. Accessed August 1, 2022.
Moncrieff, J. Persistent withdrawal and lasting damage from prescribed drugs. Joanna Moncrieff [blog]. April 1, 2019. Accessed July 16, 2022.
Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported. React Wkly. 2012;1398(2). doi:10.2165/00128415-201213980-00005
Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013 Jul 9;185(10):E455-E456. doi:10.1503/cmaj.109-4488
Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr. 2013;36:42-5. 2013 Apr 2. doi:10.18773/austprescr.2013.021
Clearfield W. Post Finasteride Syndrome. Slides for presentation to American Osteopathic Society of Rheumatic Diseases – Congress of Medical Excellence 3.0. March 21, 2021. Slides are accompanied by an undated white paper. Accessed July 16, 2022.
Grimalt R. Post-finasteride syndrome (CS2-3). 10th World Congress for Hair Research [Program]; October 31–November 3, 2017; Kyoto, Japan.
Jacobs A. Post-finasteride syndrome and the neuroendocrine system. ISHRS 24th World Congress; September 2016; Las Vegas, Nevada, USA.
Washenik K. Update on the post-finasteride controversy (LC-6). 10th World Congress for Hair Research [Program]; October 31–November 3, 2017; Kyoto, Japan.
[Anonymous]. Post Finasteride Syndrome (PFS). Submission to June 2019 meeting of Advisory Committee on Medicines, Therapeutic Goods Administration (Australia). Undated. Accessed July 16, 2022. PDF
Unpublished studies; studies in progress
Flynn R. Suicide and suicidality after exposure to finasteride [study in progress]. Research centre: European Medicines Agency, The Netherlands. Start date: January 2020.
Green A. Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden (MK-0906-162) [results in Documents tab]. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, European Medicines Agency. Final report: May 2, 2018.